CS Paper Radar

From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?

Pierre Llompart, Levent Guner, Helen Lai, Alessandro Tibo, Yijie Xu

cs.AI ·submitted 2026-10-05 14:28 UTC · v2
publishedbenchmark

Abstract

Agentic systems increasingly coordinate molecular-design tools, but it is unclear which layer of the stack limits outcomes on real projects. We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure--activity relationships, and revises its strategy accordingly. MAGI generates molecules either directly through the LLM or by delegating to REINVENT 4, with scoring services interchangeable behind a common contract. We tested it across nine retrospective lead-optimization campaigns from three pharmaceutical companies, replayed under fixed temporal cutoffs. Both routes produced valid structures: LLM proposals stayed closer to local chemistry and reached comparable or higher primary activity in fewer operations, whereas REINVENT explored broader chemical space. Whether a campaign met its objective depended on the predictive models, not on the generation route: attainment followed model accuracy on the chemistry proposed, dropping once that chemistry moved outside the model's applicability domain. Separately, a blinded evaluation asked whether the MAGI's output could pass as expert work: chemists were not able to discriminate agentic proposals from held-out compounds, and judged the SAR reasoning broadly plausible yet incomplete. Together, these results position MAGI as a coordination layer pluggable into existing computational chemistry workflows. The ceiling on real projects, however, remains currently set by scorer applicability rather than by tool orchestration.

Closest papers

Nearest neighbours by meaning across the whole index.

PharmAgents2: Towards Autonomous End-to-End Drug Discovery

cs.AI q-bio.QM ·2026-11-05 ·Haichuan Tan, Bowen Gao, Tao Huang, Jiaxin Tan, Xin Hong +20 more
similarity 0.74
Abstract

Drug discovery requires continuous scientific decision-making across a vast research space. We introduce PharmAgents2, an autonomous system for end-to-end drug discovery that combines knowledge-enhanced decision-making with organized large-scale exploration. Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context and decision-making capabilities across targets, scientific hypotheses, and discovery strategies. We introduce PharmAgents-Bench v0.1, comprising 121 questions across nine decision scenarios and three end-to-end tasks assessed with expert-defined process rubrics. PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks. In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments. For LpxH, PharmAgents2 hypothesized a previously unreported allosteric site and screened compounds against it, identifying a novel inhibitor scaffold with experimentally confirmed inhibitory activity and binding. For JAK1, it prioritized a covalent inhibition strategy and nominated compounds with experimentally demonstrated activity. Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally. PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.

0.05

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

cs.AI cs.MAq-bio.BM ·2026-11-02 ·Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang +11 more
benchmark similarity 0.72
Abstract · 63 pages, 13 figures, including Supporting Information

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

0.08

A Modular Agentic Framework for Synthetically Constrained Multi-Objective Hit-to-Lead Optimization

cs.AI cs.LGq-bio.QM ·2026-08-11 ·Kelvin P. Idanwekhai, Enes Kelestemur, Benjamin Strickland, Matthew Hart, Steini Davidsson +4 more
code/data similarity 0.72
Abstract · 22 pages, 9 figures

Hit-to-lead optimization requires iterative design of hit analogs across competing potency, selectivity, physicochemical, pharmacokinetic, safety, and synthetic constraints. We present SABLE (Synthetically-accessible Agentic Bayesian Ligand Exploration), an open-source framework that employs natural-language orchestration to guide chemical structure optimization. SABLE uses an LLM to interpret user-defined goals and route tasks, while specialized tools perform reaction-templated analog enumeration, physicochemical and ADMET property prediction, structure-based affinity scoring, and Bayesian optimization. The resulting workflow is a computational twin of the analytical and prioritization stages of the design-make-test-analyze cycle, providing provenance of each numerical output. Across single, and multi-objective optimization studies, SABLE enriches candidate sets for user-defined computational objectives while evaluating only a subset of the enumerated search space. Its modular architecture allows tools and characterization backends to be replaced by editing a simple config file, without modifying operational logic. SABLE provides an extensible decision-support framework for prioritizing synthetically constrained analogs in early-stage drug discovery.

0.26

MADDIE: Multi-Agent Drug Discovery Engine

cs.AI ·2026-10-12 ·Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao +2 more
code/data similarity 0.71
Abstract

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.

0.29

ReTRACE: Feedback-Guided LLM Agent in a Chemistry Harness for Retrosynthesis Planning

cs.AI ·2026-10-17 ·Jinxiang Xie, Yijian Zhang, Qingyuan Yi, Jianyi Wang, Hao Dong
similarity 0.70
Abstract

Computer-aided retrosynthesis has advanced through single-step prediction, tree search and route scoring, but complex targets still require judgement over the whole route, where stereochemistry, functional-group compatibility, cost and greenness interact. Here we present \textbf{\mbox{ReTRACE}} (\textbf{RE}trosynthesis with \textbf{T}ool-orchestrated \textbf{R}easoning \textbf{A}nd \textbf{C}ontext-aware \textbf{E}vidence), an agent that places a large language model (LLM) in a chemistry harness that integrates molecular tools, complementary single-step prediction engines, a purchasable starting-material library, a route memory and a multi-criterion route evaluator. Routes are judged by a new metric that combines programmatic checks with adversarial LLM review, and its verdicts are compared with a synthetic chemist's. The agent learns continually from evaluator feedback during search, diagnosing weak routes and backtracking to revise them. With Claude Opus 4.8, at least one of the top 10 routes proposed by ReTRACE passed the audit for 87.4\%, 95.0\% and 86.7\% of targets on the three benchmarks. Two prospective wet-lab syntheses show that ReTRACE route proposals can be converted into executable procedures after expert revision.

0.18

M3OS: A Monte Carlo Graph Search-Orchestrated Multi-Agent LLM System for Evidence-Traced Molecular Optimization

cs.LG q-bio.BM ·2026-09-28 ·Junjie Wang, Yaowei Jin, Ruohui Tang, Guonan Cui, Haojie Wang +5 more
similarity 0.69
Abstract

Small-molecule optimization integrates medicinal-chemistry reasoning and computational evidence through iterative, multi-objective decisions. When large language models (LLMs) reason over optimization histories stored primarily in conversational context, they must recover candidate identities, prior evaluations, and task constraints to guide subsequent decisions. We present M3OS, a multi-agent LLM system that decouples molecular-design reasoning from optimization-state management through Monte Carlo graph search. A persistent graph links evaluated candidates, parent-child transformations and evaluation evidence, while rewards and visit statistics guide LLM-assisted parent selection. Two branches combine tool-driven candidate generation with knowledge- and case-guided medicinal-chemistry editing. An execution harness controls graph updates through structured output extraction, molecular validation and task-bound evaluation. Agents receive role-specific contexts, while the graph preserves optimization trajectories beyond their active contexts. Across three molecular optimization benchmarks, M3OS achieves higher success rates than baselines, supporting the integration of persistent search state, specialized agents and controlled execution for multi-constraint optimization.

0.21

Vibe synthesis: hierarchical agentic decision-making for intent-driven multistep molecule synthesis

cs.AI physics.chem-ph ·2026-11-12 ·Jie Chen, Guikun Chen, Feng Wan, Ning Xu, Wen Liu +13 more
similarity 0.68
Abstract · 30 pages, 5 figures

The ability to construct complex molecules underpins advances in medicine and the molecular sciences. Yet long-horizon multistep synthesis requires decisions to be revised as evidence accumulates across chemically dependent operations, a capability not readily supported by artificial-intelligence tools and automated platforms organized around predefined tasks and hard-coded workflows. Here we propose and demonstrate a vibe synthesis system (VibeSyn), an intent-driven architecture in which hierarchical agents translate chemist-defined molecular objectives and accumulating evidence into adaptive decisions executed through computational tools and laboratory automation. We evaluate VibeSyn in three demonstrations of increasing scope and autonomy, progressing from evidence-grounded experimental decisions to adaptive execution of a ten-step total synthesis of catharanthine and structure-to-compound synthesis of cyclic peptides containing unnatural amino acids (uAAs). Across the long-horizon campaigns, active human input and simple confirmation account for less than 7.5% and 5.2%, respectively, of recorded workflow actions and outcomes. VibeSyn points towards a future in which chemists define synthetic intent and agent-directed laboratories autonomously navigate the evolving experimental trajectory required to deliver the target compound.

0.30

Training Large Language Models for Small-Molecule Design with Synthetic Task Scaling

cs.LG ·2026-09-04 ·Frank Hu, Shriram Chennakesavalu, Zichen Wang, Patricia Suriana, Bodhi Vani +3 more
similarity 0.68
Abstract

Designing viable drug candidates requires searching a combinatorially large and rugged chemical space for molecules that satisfy multiple, often competing, objectives. Large language models (LLMs) provide a useful generative prior for this problem because of their representational capacity, reasoning ability, and flexibility when incorporating information from the external environment. While reinforcement learning from verifiable rewards (RLVR) can be used to improve the capabilities of LLMs, many chemically relevant scoring functions require hours or even days per evaluation, making them prohibitively expensive to use directly during online training. Here, we investigate whether LLMs can learn molecular design strategies from cheaper synthetic tasks that generalize to expensive molecular lead optimization settings. We find that curriculum-based training recipes that gradually incorporate more challenging synthetic design tasks enable strong performance that surpasses that of much larger frontier models on structure-based lead optimization. Our results suggest that scaling post-training using synthetic tasks is an effective strategy for adapting LLMs to high-cost experimental scenarios that are too expensive to directly train on.

0.38